Current Tigecycline Rebate Availability
No publicly available tigecycline rebates are active as of now. Tigecycline (brand name Tygacil), made by Pfizer, faces generic competition since its core patents expired in 2021-2022, driving down prices without widespread rebate programs from manufacturers.[1]
Why No Rebates Right Now
Pfizer ended Tygacil-specific patient assistance and rebate initiatives around 2020-2021 amid generic entry. Generic versions from Sandoz, Fresenius Kabi, and others dominate hospital purchasing, where rebates are negotiated via group purchasing organizations (GPOs) like Vizient or Premier rather than direct manufacturer offers.[2] Check hospital formularies or GPO contracts for bundled deals, but these aren't open to individuals.
Cheaper Ways to Get Tigecycline
- Generic Pricing: Average wholesale price for 50mg vials is $100-200, far below Tygacil's $1,000+ peak. Use GoodRx or pharmacy discounters for outpatient scripts—cash prices start at $150/vial.[3]
- Patient Assistance Alternatives: Pfizer's patient support (PfizerRxPathways) covers some antibiotics but excludes tigecycline; try NeedyMeds or RxAssist for copay help on generics.[4]
- 340B Program: Eligible hospitals/clinics get steep discounts (up to 50% off), but that's not direct rebates for patients.
Tigecycline Patent Status and Supply Impact
Key U.S. patents (e.g., 6,706,752 for the compound) expired June 2022, with no major extensions. Pediatric exclusivity ended earlier. No active litigation blocks generics, stabilizing supply and prices—no rebate need.5 DrugPatentWatch.com
Hospital Buying Options Beyond Rebates
IDNs negotiate volume-based discounts directly with generic makers. For example:
- Sandoz tigecycline: Often $80-120/vial in GPO tenders.
- Contact wholesalers like McKesson or Cardinal for bid pricing if buying in bulk.
[1]: FDA Orange Book, Tygacil patents.
[2]: Pfizer product updates, 2021.
[3]: GoodRx pricing data, October 2023.
[4]: NeedyMeds database.